Outlook Therapeutics's total inventories for the quarter that ended in Mar. 2026 was $3.34 Mil. Outlook Therapeutics's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $3.40 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Outlook Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $-0.38.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Outlook Therapeutics's Days Inventory for the
three
months ended in Mar. 2026 was 2,082.83.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Outlook Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Outlook Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 26.78.
Outlook Therapeutics (NAS:OTLK) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Outlook Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Outlook Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Outlook Therapeutics Total Inventories Related Terms
Outlook Therapeutics Total Inventories Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Outlook Therapeutics (OTLK) has a Total Inventories of $3.34 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' Total Inventories too high?
Outlook Therapeutics' current Total Inventories is $3.34 Mil. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Total Inventories compare to INO and CBUS?
Outlook Therapeutics' Total Inventories of $3.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Outlook Therapeutics and its competitors. Outlook Therapeutics's current Total Inventories is $3.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Total Inventories of $3.34 Mil. The current Total Inventories is $3.34 Mil. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Total Inventories is $3.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score
Get the complete analysis for OTLK
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
